Abstracts tagged "Interleukins (IL) and psoriatic arthritis"

Abstract Number: 645 • 2018 ACR/ARHP Annual Meeting
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Uta Kiltz¹, Peter Kaestner², Holger Krauel², Ilka Schwarze³, Jan Brandt-Juergens⁴, Monika Maier-Peuschel⁵, Carolin Legeler⁵, Justyna Veit⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatology, Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…
Abstract Number: 2L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Philip J Mease¹, Herbert Kellner², Akimichi Morita³, Alan J. Kivitz⁴, Kim A. Papp⁵, Stella Aslanyan⁶, Beate Berner⁷, Kun Chen⁸, Ann Eldred⁸ and Frank Behrens⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Private Practice and Division of Rheumatology KHI Neuwittelsbach, München, Germany, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…
Abstract Number: 73 • 2017 ACR/ARHP Annual Meeting
Regulation of Th17 Cell Responses By IL-25
Sophie Archer, Ash Maroof, Meryn Griffiths and Stevan Shaw, UCB Pharma, Slough, United Kingdom
Background/Purpose: IL-17A is a Th17 proinflammatory cytokine that contributes to the pathophysiology of several immune-mediated inflammatory diseases including PsA; while previously underestimated, there is increasing…
Abstract Number: 618 • 2017 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
Paul Emery¹, Iain B. McInnes², Philip J Mease³, Michael Schiff⁴, Luminita Pricop⁵, Steven Shen⁵, Zailong Wang⁵ and Corine Gaillez⁶, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Colorado, Denver, CO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Achieving, sustaining, and improving clinical responses to biologics in PsA are important parts of EULAR and GRAPPA recommendations aimed to optimize treatment goals.1,2 Here…
Abstract Number: 2148 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Philip J. Mease¹, Iain B. McInnes², Bruce Kirkham³, Arthur Kavanaugh⁴, Proton Rahman⁵, Désirée van der Heijde⁶, Robert B.M. Landewé⁷, P Nash⁸, Luminita Pricop⁹, Zailong Wang¹⁰ and Shephard Mpofu¹¹, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Medicine, Memorial University, St John's, NF, Canada, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁸Department of Medicine, University of Queensland, Brisbane, Australia, ⁹Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In the Phase 3, randomized, double-blind, placebo (PBO)-controlled, FUTURE 1 study (NCT01392326), the anti–interleukin-17A monoclonal antibody secukinumab provided rapid and significant improvements in key…
Abstract Number: 2872 • 2015 ACR/ARHP Annual Meeting
Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
Mark C. Genovese¹, Philip J. Mease², Maria Greenwald³, Christopher T. Ritchlin⁴, Andre Beaulieu⁵, Atul A. Deodhar⁶, Richard Newmark⁷, JingYuan Feng⁸, Ngozi Erondu⁹ and Ajay Nirula¹⁰, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Desert Medical Advances, Palm Desert, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Faculty of Medicine, University of Laval, Quebec, QC, Canada, ⁶Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷Clinical Affairs, Amgen, Thousand Oaks, CA, ⁸Amgen Inc., Thousand Oaks, CA, ⁹Inflammation, Amgen, Inc., Thousand Oaks, CA, ¹⁰Amgen Inc, Thousand Oaks, CA
Background/Purpose: The interleukin-17 (IL-17) cytokine family plays a key role in the pathogenesis of psoriatic diseases of skin and joint. Brodalumab is a fully human…
Abstract Number: 1557 • 2014 ACR/ARHP Annual Meeting
Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
Mark C Genovese¹, Philip J. Mease², Maria W. Greenwald³, Christopher T. Ritchlin⁴, A Beaulieu⁵, Atul A. Deodhar⁶, Richard Newmark⁷, JingYuan Feng⁸, Ngozi Erondu⁹ and Ajay Nirula¹⁰, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Desert Medical Advances, Palm Desert, CA, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Bureau 360, Centre de Rhumatologie, St-Louis, QC, Canada, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Clinical Affairs, Amgen, Thousand Oaks, CA, ⁸Amgen Inc, Thousand Oaks, CA, ⁹Inflammation, Amgen, Inc., Thousand Oaks, CA, ¹⁰Amgen, Thousand Oaks, CA
Background/Purpose: Interleukin-17 (IL-17) plays a role in the pathogenesis of psoriatic disease of both skin and joint. We sought to assess long-term efficacy and safety…
Abstract Number: 2487 • 2013 ACR/ARHP Annual Meeting
Role Of IL-33 In The Development Of Premature Atherosclerosis In Psoriatic Arthritis Patients
Priscilla Ching-han Wong¹, Qing Shang², Cheuk-Man Yu² and Lai Shan Tam², ¹Medicine and Therapeutics, Prince of Wales hospital, New Territories, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Interleukin 33 (IL-33) is a newly identified member of the IL-1 cytokine family. It involves in T-cell mediated immune responses through the activation of…
Abstract Number: 817 • 2013 ACR/ARHP Annual Meeting
Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
MC Genovese¹, Philip J. Mease², Maria W. Greenwald³, Christopher T. Ritchlin⁴, André Beaulieu⁵, Atul A. Deodhar⁶, Richard Newmark⁷, JingYuan Feng⁸, Ngozi Erondu⁸ and Ajay Nirula⁸, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Desert Medical Advances, Palm Desert, CA, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Faculty of Medicine, Laval University, Quebec, QC, Canada, ⁶Oregon Health and Science University, Portland, OR, ⁷Clinical Development, Amgen Inc, Thousand Oaks, CA, ⁸Amgen Inc, Thousand Oaks, CA
Background/Purpose: Psoriasis-associated skin and joint disorders are characterized by ongoing inflammation mediated by similar molecular pathways. IL-17 plays a potential role in the pathogenesis and…
Abstract Number: L7 • 2013 ACR/ARHP Annual Meeting
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
Alice Gottlieb¹, Richard Langley², Sandra Philipp³, Ruvie Martin⁴, Charis Papavassilis⁵ and Shephard Mpfofu⁵, ¹Tufts Medical Center, Boston, MA, ²Dalhousie University, Halifax, NS, Canada, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Novartis Pharma AG, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC; AIN457), a fully human anti–IL-17A monoclonal antibody, has demonstrated efficacy in phase 3 trials for treatment of plaque psoriasis and preliminary results…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].